---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019381"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:08:13.789704+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible

## Summary
- Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.
- Performance-based compensation includes up to 18 million unvested 4-year warrants, vesting upon milestones such as FDA approval or sale of program.
- First SOW involves re-analysis of HP2001 clinical study data and preparing FDA meeting request (Type B/C/D).
- Board adopted 2025 Equity Incentive Plan reserving 20 million shares; subject to shareholder approval within 12 months.
- Consulting agreement continues indefinitely; each project governed by separate SOWs.

## SEC filing metadata
- accession: 0001493152-25-019381
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000149315225019381/0001493152-25-019381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000149315225019381/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019381
- JSON: https://secwatch.observer/filing/0001493152-25-019381.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.